Takeda Pharmaceutical Li... (TAK)
NYSE: TAK
· Real-Time Price · USD
14.96
0.16 (1.08%)
At close: Aug 15, 2025, 12:06 PM
Takeda Pharmaceutical Revenue Breakdown
| Period Ending | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 |
|---|---|---|---|---|---|---|
| Gastroenterology Revenue | 1,357B | 1,216.2B | 1,094.5B | 875.68B | 777.8B | 697.9B |
| Gastroenterology Revenue Growth | +11.58% | +11.12% | +24.99% | +12.58% | +11.45% | n/a |
| Neuroscience Revenue | 565.82B | 627.01B | 637.71B | 482.29B | 417.3B | 438.52B |
| Neuroscience Revenue Growth | -9.76% | -1.68% | +32.22% | +15.58% | -4.84% | n/a |
| Oncology Revenue | 560.43B | 462.36B | 438.74B | 468.73B | 416.51B | 420.96B |
| Oncology Revenue Growth | +21.21% | +5.38% | -6.40% | +12.54% | -1.06% | n/a |
| Other Product Revenue | 257.39B | 368.91B | 454.6B | 624.15B | 574.07B | 704.76B |
| Other Product Revenue Growth | -30.23% | -18.85% | -27.17% | +8.72% | -18.54% | n/a |
| PDT Immunology Revenue | 1,032.7B | 818.57B | 678.44B | 506.95B | 420.39B | 394.17B |
| PDT Immunology Revenue Growth | +26.15% | +20.65% | +33.83% | +20.59% | +6.65% | n/a |
| Rare Diseases Revenue | 752.82B | 770.7B | 723.44B | n/a | 591.75B | 634.89B |
| Rare Diseases Revenue Growth | -2.32% | +6.53% | n/a | n/a | -6.80% | n/a |
| Vaccines Revenue | 55.41B | n/a | n/a | n/a | n/a | n/a |
| Vaccines Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|
| Asia, Excluding Japan And China Revenue | 99.39B | 966.84B | 842.67B | 739.17B | 666.18B | 645.53B | 405.64B |
| Asia, Excluding Japan And China Revenue Growth | -89.72% | +14.73% | +14.00% | +10.96% | +3.20% | +59.14% | n/a |
| China Revenue | 191.74B | 451.39B | 512.04B | 658.98B | 559.75B | 592.79B | 571.02B |
| China Revenue Growth | -57.52% | -11.85% | -22.30% | +17.73% | -5.57% | +3.81% | n/a |
| Europe And Canada Revenue | 1,055.3B | 198.1B | 160.38B | 128.47B | 121.64B | 143.46B | 88.11B |
| Europe And Canada Revenue Growth | +432.69% | +23.52% | +24.84% | +5.61% | -15.21% | +62.81% | n/a |
| Japan Revenue | 418.46B | 117.91B | 95.18B | 68.94B | 68.52B | 71.26B | 38.31B |
| Japan Revenue Growth | +254.90% | +23.88% | +38.05% | +0.62% | -3.85% | +85.98% | n/a |
| Latin America Revenue | 235.85B | 2,195.7B | 2,103.8B | 1,714.4B | 1,567.9B | 1,595.9B | 828.99B |
| Latin America Revenue Growth | -89.26% | +4.37% | +22.71% | +9.34% | -1.75% | +92.52% | n/a |
| Other Countries Not Separately Reported Revenue | 128.85B | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Countries Not Separately Reported Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue | 2,379.7B | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 295.9B | 270.59B | 268.28B | 270.03B | 285.23B | 267.52B | 252.95B | 248.11B | 254.8B | 262.3B | 248.73B | 231.48B | 223.43B | 231.08B | 212.01B | 219.84B | 234.39B | 222.64B | 216.26B | 202.37B | 253.06B | 249.21B | 223.26B | 239.21B | 269.92B | 153.89B | 148.75B | 145.03B | 171.77B | 159.08B | 151.4B | 145.87B | 179.69B | 148.43B | 145.98B | 144.96B | 175.25B | 162.03B | 151.8B | 161.69B | 174.58B |
| Selling, General, and Administrative Revenue Growth | +9.35% | +0.86% | -0.65% | -5.33% | +6.62% | +5.76% | +1.95% | -2.62% | -2.86% | +5.45% | +7.45% | +3.60% | -3.31% | +8.99% | -3.56% | -6.21% | +5.27% | +2.95% | +6.86% | -20.03% | +1.54% | +11.63% | -6.67% | -11.38% | +75.39% | +3.45% | +2.57% | -15.57% | +7.98% | +5.07% | +3.79% | -18.82% | +21.06% | +1.68% | +0.71% | -17.29% | +8.16% | +6.74% | -6.12% | -7.38% | n/a |
| Research and Development Revenue | 216B | 170.19B | 175.56B | 168.46B | 195.86B | 187.38B | 183.95B | 162.74B | 160.94B | 174.63B | 154.15B | 143.61B | 143.63B | 128.38B | 131.6B | 122.48B | 113.29B | 117.57B | 118.16B | 106.82B | 139.31B | 122.71B | 113.5B | 116.87B | 139.41B | 77.46B | 79.47B | 71.97B | 88.78B | 81.56B | 79.41B | 75.69B | 88.5B | 71.83B | 75.42B | 76.55B | 92.03B | 92.53B | 80.38B | 80.99B | 132.87B |
| Research and Development Revenue Growth | +26.91% | -3.06% | +4.22% | -13.99% | +4.52% | +1.87% | +13.03% | +1.12% | -7.84% | +13.29% | +7.34% | -0.01% | +11.88% | -2.45% | +7.45% | +8.11% | -3.64% | -0.50% | +10.61% | -23.32% | +13.53% | +8.12% | -2.88% | -16.17% | +79.97% | -2.52% | +10.42% | -18.94% | +8.85% | +2.72% | +4.91% | -14.48% | +23.21% | -4.75% | -1.48% | -16.82% | -0.54% | +15.11% | -0.75% | -39.04% | n/a |